Mission
NIBRT’s mission is to strengthen Ireland’s position as a location of choice for the manufacture of medicines.
NIBRT delivers on its mission by:
- Delivering training that develops the highly skilled workforce needed to make biologic medicines.
- Advancing bioprocessing knowledge and innovation through research, that translates into manufacturing practice and delivers positive impact across the industry.
- Strengthening Ireland’s global biopharma reputation through:
- Provision of world-leading training, with facilities, capabilities and programmes not found anywhere else.
- Setting the international benchmark for biopharma workforce development.
- Building high impact research partnerships with industry and academia from around the world.
NIBRT Strategy 2024 - 2028
The process of developing the NIBRT strategic business plan 2024-2028 concluded in late 2023. By engaging with a range of stakeholders and analysing the wider biopharma operational environment, a number of important trends were identified.Â
In response to these trends and associated opportunities, and aligned with NIBRT’s core mission, NIBRT has developed an ambitious strategy that focuses on five strategic priorities. This new strategy and associated business plan for the period 2024-2028 has been approved by the NIBRT Board, and core operational and capital-based state investment has been approved by the Board of IDA Ireland for delivery over the next five years.
STRATEGIC PRIORITIES 2024-2028
Based on our analysis of the market, stakeholder consultations (including with staff and clients) and our assessment of the evolving global environment, NIBRT will focus on five key strategic priorities for 2024-2028, summarised as follows:
NIBRT Culture
NIBRT strives to foster a highly open, inclusive, progressive, and innovation-friendly workplace, which recognises excellent performance while also respecting diversity and equality in all aspects of our activity.  Our culture is created by our people and guided by our set of values depicted in CIRCLES.
